- Home
- Daily Diary
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
-0.80| Last Update: 06/19/13 - 4:00 PM EDT |
| Volume: 7,809,066 |
| YTD Performance: 43.76% |
| Open: $46.60 |
| Previous Close: $46.85 |
| 52 Week Range: $30.64 - $49.57 |
| Oustanding Shares: 1,642,551,939 |
| Market Cap: 76,280,112,047 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $0.45 | $0.46 | $1.81 | $2.11 |
| Number of Analysts | 10 | 9 | 13 | 11 |
| High Estimate | $0.47 | $0.48 | $1.85 | $2.42 |
| Low Estimate | $0.43 | $0.43 | $1.78 | $1.93 |
| Prior Year | $0.48 | $0.37 | $1.99 | $1.81 |
| Growth Rate (Year over Year) | -6.87% | 24.62% | -9.08% | 16.57% |
There is going to be a fear of recession if rates keep going up.
Jim Cramer looks at stocks moving on cancer-fighting develompents, in a discussion with Mad Money Research Director Nicole Urken
Here we go again: What does this have to do with the price-to-earnings ratio of Bristol Myers?
UBS Healthcare Conf. UBS Global Healthcare Conference
Bristol-Myers upgraded at LeerinkBMY was upgraded from Market Perform to Outperform, Leerink Swann said. Cancer product pipeline should drive future growth.
<I>TheStreet</I> senior columnist Adam Feuerstein discusses the winners and losers from the research abstracts ahead of the ASCO cancer conference.
Bristol-Myers target boosted at GoldmanShares of BMY now seen reaching $48, according to Goldman Sachs. PD-1 data has exceeded expectations. Buy rating.
TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.